Tharimmune, Inc.
Clinical-stage biotech developing therapies for immunology, oncology, & opioid effects.
THAR | US
Overview
Corporate Details
- ISIN(s):
- US4327051011 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 1200 ROUTE 22 EAST, 8807 BRIDGEWATER
- Website:
- https://tharimmune.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation, and oncology. The company's lead clinical asset, TH104, is being developed via a 505(b)2 pathway to treat respiratory and nervous system depression in personnel who may be exposed to high-potency opioids. The pipeline also includes TH104 for chronic pruritus in primary biliary cholangitis and TH023 for autoimmune diseases. Tharimmune is also advancing an early-stage multispecific biologic platform, its proprietary EpiClick™ Technology, designed to target unique epitopes in various solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tharimmune, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tharimmune, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tharimmune, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
